Press Release (ePRNews.com) - New York, NY (USA) - May 12, 2017 - Global Private Group has provided a USD 385 Million Series C Financing to a Healthcare Therapeutics Company.
Global Private Group was the sole funder.
The initial tranche of USD 385 Million will enable the Healthcare Therapeutics Company to progress its lead product into clinical phase three studies in community-acquired bacterial pneumonia (CABP) and to continue the development of its product pipeline.
Chief Executive Officer of the Healthcare Therapeutics Company says: “We are delighted to have attracted investment from some of the world’s leading healthcare investors, Global Private Group. It is validation of our approach in developing the new antibiotic class, which has a unique mechanism of action thereby helping to combat the current and evolving emergence of resistance to currently available antibiotics. We appreciate the commitment of our existing investors and the continued confidence they have shown in our Company. We welcome Global Private Group to the Supervisory Board and look forward to benefiting from their expertise as we advance our programs.”
Development Partner at Global Private Group says: “We are excited to work with the Healthcare Therapeutics Company in the development of drugs to address the urgent issues around antibiotic resistance. We believe they are one of a few development stage companies with a truly novel antibiotic product ready for phase 3 studies and with a clear path to commercialization. We are pleased to support the company as it enters its next stage of growth.”
The Chairman of the Supervisory Board of the Healthcare Therapeutics Company says: “The rapid spread of multi-drug resistance is a growing public health threat recognized by global policy makers as Governments commit resources and funding to tackle this problem. The development of novel antibiotics with a unique mechanism of action against these pathogens is critically important in developing a new generation of drugs. This Series C is a strong financial and scientific endorsement and provides us with a solid foundation to build a patient-centric global biopharmaceutical company.”
Chief development officer at clinical genomics enterprise says: “The unrivalled integrated end-to-end solution provided by our platform offers multiple advantages for our partners.”
Global Private Group is one of the largest and most experienced project finance groups in the world compromising more than 300 dedicated specialists in our offices worldwide who are fully qualified to provide financial services and products.
Stable financing, efficient execution, expert solutions and customer service are how we help clients succeed.
Our broad range of lending products in the areas of corporate lending and investment banking, combined with access to strong capital base; allows us to execute financing that supports your business objectives. Our deal professionals’ industry expertise and attention to your goals during every step of the loan process allows us to offer solutions that help you achieve success.
GLOBAL PRIVATE GROUP Source : GLOBAL PRIVATE GROUP